| __timestamp | Celldex Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 305409000 |
| Thursday, January 1, 2015 | 33837000 | 377080000 |
| Friday, January 1, 2016 | 35979000 | 432829000 |
| Sunday, January 1, 2017 | 25003000 | 496079000 |
| Monday, January 1, 2018 | 19269000 | 557616000 |
| Tuesday, January 1, 2019 | 15426000 | 658498000 |
| Wednesday, January 1, 2020 | 14456000 | 770456000 |
| Friday, January 1, 2021 | 20488000 | 840100000 |
| Saturday, January 1, 2022 | 27195000 | 944700000 |
| Sunday, January 1, 2023 | 30914000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Unlocking the unknown
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Vertex Pharmaceuticals Incorporated and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Vertex Pharmaceuticals has consistently outpaced Celldex in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Vertex's SG&A expenses were approximately 3.7 times higher than in 2014, showcasing a robust growth trajectory. Meanwhile, Celldex's expenses have fluctuated, peaking in 2016 and showing a resurgence in 2023. This divergence highlights the different strategic paths these companies have taken, with Vertex investing heavily in administrative capabilities to support its expanding operations. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Alnylam Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Incyte Corporation
Vertex Pharmaceuticals Incorporated and Bio-Techne Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs MannKind Corporation
Regeneron Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Viatris Inc. vs Celldex Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? HUTCHMED (China) Limited or Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Taro Pharmaceutical Industries Ltd. and Celldex Therapeutics, Inc.